News | October 09, 2022
Pfizer acquires Global Blood Therapeutics
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Subscribe To Our Newsletter & Stay Updated
